| Bioactivity | SF0166 is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. SF0166 inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. SF0166 decreases neovascularization in the oxygen-induced retinopathy mouse model[1]. |
| Invitro | SF0166 (0.5-4 μg; 12天; 鸡胚绒毛尿囊膜 (CAM) 模型) 以剂量依赖的方式抑制碱性成纤维细胞生长因子刺激的血管生成[1]。 |
| In Vivo | SF0166 (双侧眼局部滴注 5% SF0166) 抑制 129SVE 新生小鼠氧诱导视网膜病变 (OIR) 模型视网膜新生血管[1]。 Animal Model: |
| Name | SF0166 |
| CAS | 1621332-91-9 |
| Formula | C23H27F2N5O4 |
| Molar Mass | 475.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Askew BC, et, al. Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered αvβ3 Integrin Antagonist, for the Treatment of Retinal Diseases. J Pharmacol Exp Ther. 2018 Aug;366(2):244-250. |